Date: 2012-06-12
Type of information: Production agreement
Compound: ANX-188 (purified poloxamer 188)
Company: ADVENTRX Pharmaceuticals (USA) Pierre Fabre Medicament (France)
Therapeutic area: Hematological diseases
Type agreement: production
manufacturing
Action mechanism: ADVENTRX Pharmaceuticals \'s lead product candidate, ANX-188 is a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has potential application in treating a wide range of diseases and conditions, such as complications arising from sickle cell disease.
Disease:
Details: ADVENTRX Pharmaceuticals and Pierre Fabre Medicament have entered into a multi-year agreement under which Pierre Fabre, as contract manufacturer, will produce the active ingredient in ANX-188 (purified poloxamer 188) for use in clinical trials, including the Phase 3 study of ANX-188 that ADVENTRX plans to initiate this year.
Pierre Fabre has made the choice to manufacture its own products to guarantee their quality through total control of the entire supply chain. Among its 9 production units, a dedicated unit of Pierre Fabre located in Gaillac (Tarn, South West of France) specialises in supercritical fluids. Created in 2004, the Supercritical Fluids Division has developed proprietary knowledge in supercritical fluids technology for pharmaceutical applications and commercializes its cutting-edge expertise to external partners. Specialized in the purification of molecules using supercritical fluids, this Division has also developed different green patented processes (Formulplex®, Formuldisp® and Formulcoat®) for pre-formulation of Active Pharmaceutical Ingredients. Its facilities are composed of 2 units (development and production).
Financial terms:
Latest news:
